
Nephros NEPH
$ 5.07
-1.74%
Quarterly report 2025-Q3
added 11-06-2025
Nephros Interest Expense 2011-2026 | NEPH
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Nephros
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 K | 20 K | 41 K | 110 K | 195 K | 172 K | 302 K | 172 K | 42 K | 483 K | 351 K | - | 12 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 483 K | 2 K | 158 K |
Quarterly Interest Expense Nephros
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15 K | -32 K | -21 K | - | -43 K | 7 K | 7 K | - | 10 K | -11 K | 1 K | - | 4 K | 6 K | 7 K | - | 10 K | 11 K | 13 K | - | 22 K | 30 K | 43 K | - | 48 K | 46 K | 46 K | - | 32 K | 28 K | 86 K | - | 88 K | 64 K | 66 K | - | 65 K | 30 K | 14 K | - | 9 K | 9 K | 11 K | - | 65 K | 17 K | 195 K | - | 5 K | 24 K | 24 K | - | - | - | -2 K | - | 12 K | 12 K | 12 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 K | -43 K | 24.5 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
Baxter International
BAX
|
408 M | $ 20.66 | 1.27 % | $ 10.5 B | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 205.09 | 1.16 % | $ 59 B | ||
|
Ekso Bionics Holdings
EKSO
|
-1 K | $ 8.15 | -7.6 % | $ 164 M | ||
|
Alcon
ALC
|
192 M | $ 80.67 | -0.38 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
-326 K | $ 42.59 | 1.96 % | $ 2 B | ||
|
electroCore
ECOR
|
6.3 M | $ 5.15 | 6.19 % | $ 28.4 K | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 84.98 | 2.36 % | $ 4.28 B | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 10.02 | -8.29 % | $ 409 M | ||
|
Harvard Bioscience
HBIO
|
-227 K | $ 0.66 | -1.92 % | $ 28 M | ||
|
The Cooper Companies
COO
|
-16.4 M | $ 83.38 | -0.63 % | $ 16.6 B | ||
|
ICU Medical
ICUI
|
107 M | $ 152.88 | 1.7 % | $ 3.73 B | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 114.49 | 0.43 % | $ 5.55 B | ||
|
InfuSystem Holdings
INFU
|
1.4 M | $ 8.9 | -0.11 % | $ 184 M | ||
|
iRhythm Technologies
IRTC
|
1.25 M | $ 188.16 | 0.41 % | $ 5.87 B | ||
|
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | ||
|
Repro Med Systems
KRMD
|
561 K | $ 5.79 | 3.02 % | $ 264 M | ||
|
LeMaitre Vascular
LMAT
|
205 K | $ 85.05 | 1.55 % | $ 1.91 B | ||
|
Masimo Corporation
MASI
|
300 K | $ 138.18 | 0.8 % | $ 7.36 B | ||
|
Merit Medical Systems
MMSI
|
-711 K | $ 93.33 | 1.83 % | $ 5.43 B | ||
|
Microbot Medical
MBOT
|
2 K | $ 2.19 | 3.55 % | $ 22.3 M | ||
|
Milestone Scientific
MLSS
|
60.3 K | $ 0.29 | 2.24 % | $ 23.1 M | ||
|
Envista Holdings Corporation
NVST
|
-100 K | $ 23.52 | 2.53 % | $ 4.05 B | ||
|
OraSure Technologies
OSUR
|
-380 K | $ 2.65 | 5.38 % | $ 197 M | ||
|
Pro-Dex
PDEX
|
533 K | $ 41.83 | 4.47 % | $ 138 M | ||
|
Predictive Oncology
POAI
|
3 | $ 6.85 | 3.24 % | $ 37.4 M | ||
|
Pulse Biosciences
PLSE
|
983 K | $ 14.71 | -3.26 % | $ 707 M | ||
|
Repligen Corporation
RGEN
|
8.12 M | $ 165.12 | -2.32 % | $ 9.2 M | ||
|
ResMed
RMD
|
3.2 M | $ 250.85 | 1.07 % | $ 36.6 B | ||
|
BioLife Solutions
BLFS
|
497 K | $ 24.91 | -1.97 % | $ 1.15 B | ||
|
STERIS plc
STE
|
8.4 M | $ 260.64 | 0.52 % | $ 25.7 B | ||
|
Stereotaxis
STXS
|
1.1 M | $ 2.57 | -1.35 % | $ 207 M | ||
|
Retractable Technologies
RVP
|
227 K | $ 0.76 | -0.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
815 K | $ 22.43 | 1.08 % | $ 1.1 B | ||
|
Utah Medical Products
UTMD
|
256 K | $ 58.5 | 1.39 % | $ 212 M | ||
|
Teleflex Incorporated
TFX
|
57 M | $ 110.0 | -13.07 % | $ 5.15 B | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 274.0 | -1.62 % | $ 20 B | ||
|
DENTSPLY SIRONA
XRAY
|
12 M | $ 12.53 | 1.25 % | $ 2.55 B |